Cargando…

Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design

Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance with monotherapy, practical limits on numbers of treatment arms for component dose combinations, and limited appli...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lyons, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7965837/ https://www.ncbi.nlm.nih.gov/pubmed/33440076 http://dx.doi.org/10.1002/psp4.12591

Ejemplares similares

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Pretomanid for tuberculosis treatment: an update for clinical purposes
por: Occhineri, Sara, et al.
Publicado: (2022)

An Exposure-Response Perspective on the Clinical Dose of Pretomanid
por: Nedelman, Jerry R., et al.
Publicado: (2020)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023)

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021)

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
por: Li, Si-Yang, et al.
Publicado: (2023)

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
por: Bateson, Anna, et al.
Publicado: (2022)

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
por: Li, Hanbin, et al.
Publicado: (2019)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Male reproductive hormones in patients treated with pretomanid
por: Boekelheide, K., et al.
Publicado: (2022)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
por: Berry, Catherine, et al.
Publicado: (2022)

Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro
por: Hu, Minghao, et al.
Publicado: (2020)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers
por: Li, Mengchun, et al.
Publicado: (2020)

Guiding model‐driven combination dose selection using multi‐objective synergy optimization
por: Gevertz, Jana L., et al.
Publicado: (2023)

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis
por: Jung, Jin Ah, et al.
Publicado: (2015)

Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date
por: Stancil, Stephani L, et al.
Publicado: (2021)

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
por: Bruning-Barry, Rebecca, et al.
Publicado: (2022)

Short and Efficient Synthesis of the Antituberculosis Agent Pretomanid from (R)-Glycidol
por: Lucas, Tobias, et al.
Publicado: (2023)

Optimal control for colistin dosage selection
por: Gontijo, Aline Vidal Lacerda, et al.
Publicado: (2021)

Design of Membrane Active Peptides Considering Multi-Objective Optimization for Biomedical Application
por: Röckendorf, Niels, et al.
Publicado: (2022)

Profiles of direct oral anticoagulants and clinical usage—dosage and dose regimen differences
por: Ieko, Masahiro, et al.
Publicado: (2016)

1411. Noninvasive Assessment of Intralesional Antimicrobial Concentration-Time Profiles in Pulmonary and Central Nervous System Tuberculosis using Dynamic (18)F-Pretomanid Positron Emission Tomography
por: Mota, Filipa, et al.
Publicado: (2021)

Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling
por: Mehta, Krina, et al.
Publicado: (2023)

Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)
por: Baptista, Rafael, et al.
Publicado: (2018)

Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid
por: Thompson, Andrew M., et al.
Publicado: (2017)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice
por: Ambroso, Jeffrey L., et al.
Publicado: (2022)

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling
por: Zou, Yuanxi, et al.
Publicado: (2022)

Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type
por: Wang, Yifan, et al.
Publicado: (2023)

Pharmacometric approach to assist dosage regimen design in neonates undergoing therapeutic hypothermia
por: Matcha, Saikumar, et al.
Publicado: (2021)

Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations
por: Karalis, Vangelis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4tbafl38t1jt0gs9rirt6e3r15